(RTTNews) - Eisai Co., Ltd. (4523.T) and Biogen Inc. (BIIB) presented long-term data from the Phase 3 Clarity AD trial showing that continuous treatment with LEQEMBI (lecanemab-irmb) provided sustained benefits in patients with early Alzheimer's disease.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.
